Clinical outcome of granulocyte transfusion therapy for the treatment of refractory infection in neutropenic patients with hematological diseases
AbstractNeutropenic patients with hematological diseases are prone to severe infections. Granulocyte transfusion therapy (GTX) is considered as a logical therapeutic approach for these problems. However, the efficacy and complications of GTX have not been well identified. We retrospectively analyzed the clinical outcomes of GTX therapy in our hospital from 2009 to 2015. After 117 granulocyte transfusions for 47 patients, 72.3% of these patients ’ infections were effectively improved, and the overall survival rates at 30 and 120 days were 66.0 and 57.5%, respectively. The patients who experienced neutrophil recov...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
AbstractWith tyrosine kinase inhibitors (TKI), chronic myeloid leukemia (CML) patients are achieving similar rates of survival to the general population and some treatment aspects such as adherence and drug-to-drug interactions (DDI) are becoming increasingly important. Our aim was to investigate the frequency and real clinical consequences of DDI between TKI and concurrent medications in CML. We performed a retrospective multicenter study including 105 patients receiving 134 TKI treatments. Sixty-three patients (60%) had at least one potential DDI. The mean number of concomitant medications was 4.8 (0 –19). The mean...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Conviction in the face of affliction: a case series of Jehovah ’s Witnesses with myeloid malignancies
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia
AbstractHeparin-induced thrombocytopenia (HIT) is a serious complication of the administration of heparin and its derivatives. Non-heparin anticoagulants such as argatroban and fondaparinux are widely used in the management of HIT to compare the effectiveness of argatroban and fondaparinux in the resolution of thrombocytopenia and to compare clinical outcomes in patients with isolated HIT. A retrospective cohort analysis was performed at King Abdulaziz Medical City (KAMC) on patients diagnosed with isolated HIT between 31 Jan, 2014 and 30 June, 2017. Demographics data, non-heparin anticoagulants, related laboratory results...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus
In this study, we analyzed the efficacy and side effect of sirolimus on refractory/relapsed aPRCA and investigated the possible mechanism of sirolimus on immune regulation. Twenty-one patients with refractory/relapsed aPRCA were enrolled in this study and were administered with sirolimus. Totally, 76.2% of patients responded to the sirolimus with 42.9% complete response during the experimental period. The median time for reaction was 4  months. Side effects were tolerable including infections; mild oral mucositis; sinus tachycardia, the increase of creatinine, transaminase, triglyceride, or cholesterol; and thrombocyt...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database
In conclusion, incidence of IHD requires closer monitoring in nilotinib-treated patients. More detailed investigations for determining the most useful tool to predict VAE incidence and long-term analysis of therapy-related VAE cases are needed for improving safety during TKI therapy. (Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Localized pain-causing JAK2 -V617F-positive myeloproliferation with normal peripheral blood values
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Hypertransaminasemia revealing a clinically silent muscular dystrophy in a child with sickle cell disease
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation
AbstractProgrammed death 1 (PD-1) activation triggers an immune checkpoint resulting in inhibition of T cells that leads to peripheral tolerance. SomePD-1 polymorphisms have been described and associated with the development of autoimmune diseases or cancer predisposition, but there are few data concerning the relevance of such polymorphisms on the clinical outcome after allogeneic hematopoietic stem cell transplant (alloHSCT). We analyzed the distribution of the SNPs PD-1.1G/A (rs36084323) and PD-1.3G/A (rs11568821) genotypes of the donor in a cohort of 1485 alloHSCT from HLA-identical sibling donors. We found an increase...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Severe anemia after trans-catheter arterial chemoembolization —an unusual presentation of hemoglobin Zurich
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment
In this study, we investigated the effect of CD49d and CXCR4 expressions on survival of CLL cells. Primary CLL cells were cultured with CD49d ligand, VCAM-1, or bone marrow stromal cells (BMSCs); then, apoptosis and immunophenotype analyses were performed. VCAM-1 treatment could not induce direct apoptosis protection or immunophenotype change on the CD49d-expressing CLL cells, but resulted in actin reorganization. The BMSC-induced apoptosis protection was independent from the presence of CD49d expression of CLL cells, but showed an inverse correlation with their CXCR4 expression level. We suppose that CD49d contributes to ...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis
AbstractBone marrow fibrosis (MF) in myelodysplastic syndromes (MDS) is associated with an adverse prognosis. It is likely that molecular changes similar to those in primary myelofibrosis (PMF) lead to MDS-MF, but gene expression profiling has not yet been carried out. We analysed bone marrow biopsy samples by PCR, qPCR (45 transcripts per sample), and immunohistochemistry from MDS patients with fibrosis (n = 70/119; including 19/70 MF0 >  MF follow-up cases), MDS without fibrosis (n = 49/119), and 33 controls. SRSF2 and JAK2 mutations were detectable in up to 13% including 3/19...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Routine surveillance imaging in follicular lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Would you think of histiocytic sarcoma in this fine-needle aspiration?
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Drug-induced liver failure due to rivaroxaban
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis
AbstractAlthough the survival rate of diffuse large B cell lymphoma (DLBCL) has increased with years, there are still patients who do not achieve complete remission or who relapse, especially patients with activated B cell-like (ABC) DLBCL. Bortezomib, a proteasome inhibitor, has shown activity in diffuse large B cell lymphoma, especially in the subtype of ABC DLBCL. We conducted a meta-analysis to compare the efficacy and adverse events in bortezomib-containing regimens with standard R-CHOP regimen in treating DLBCL. Our results show that comparing to standard R-CHOP regimen, bortezomib-containing regimen could not prolon...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study
AbstractIn a prospective randomized study, treatment for aplastic anemia (AA) with rabbit antithymocyte globulin (r-ATG) and cyclosporine showed inferior hematological response and survival in comparison to horse antithymocyte globulin (h-ATG) and cyclosporine. However, h-ATG was discontinued in most Asian, South American, and European countries, where r-ATG became the only ATG formulation available. We retrospectively evaluated consecutive patients with acquired AA who received either rabbit (n = 170) or horse (n = 85) ATG and cyclosporine for first-line treatment from 1992 to 2014 in seven ref...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Fatigue at baseline is associated with geriatric impairments and represents an adverse prognostic factor in older patients with a hematological malignancy
AbstractProspective data on fatigue in elderly persons with a hematological malignancy are rare. We aimed to determine the prevalence of fatigue and its association with clinical outcome and geriatric impairments in older individuals newly diagnosed with blood cancer. The EORTC QLQ-C30 and a multidimensional geriatric assessment (MGA) were performed in parallel in 149 consecutive patients aged>  67 years (median 77.8 years) at Innsbruck Medical University between January 2009 and April 2016. Fatigue as defined by EORTC QLQ-C30 was the most prevalent symptom (84%) and was significantly associated with se...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
This study aimed to answer whether the omission of vincristine due to neurotoxicity affects patient outcome. A Swedish cohort of patients primarily treated with curative intent for DLBCL or high-grade malignant B cell lymphoma was retrospectively analyzed. In total, 541 patients treated between 2000 and 2013 were included. Omission of VCR was decided in 95 (17.6%) patients and was more often decided during the last three cycles (n = 86, 90.5%). The omission of VCR did not affect disease-free or overall survival neither in the whole cohort nor in elderly patients. On the contrary, the relative dose intensity o...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Clinical outcome of granulocyte transfusion therapy for the treatment of refractory infection in neutropenic patients with hematological diseases
AbstractNeutropenic patients with hematological diseases are prone to severe infections. Granulocyte transfusion therapy (GTX) is considered as a logical therapeutic approach for these problems. However, the efficacy and complications of GTX have not been well identified. We retrospectively analyzed the clinical outcomes of GTX therapy in our hospital from 2009 to 2015. After 117 granulocyte transfusions for 47 patients, 72.3% of these patients ’ infections were effectively improved, and the overall survival rates at 30 and 120 days were 66.0 and 57.5%, respectively. The patients who experienced neutrophil recov...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
AbstractWith tyrosine kinase inhibitors (TKI), chronic myeloid leukemia (CML) patients are achieving similar rates of survival to the general population and some treatment aspects such as adherence and drug-to-drug interactions (DDI) are becoming increasingly important. Our aim was to investigate the frequency and real clinical consequences of DDI between TKI and concurrent medications in CML. We performed a retrospective multicenter study including 105 patients receiving 134 TKI treatments. Sixty-three patients (60%) had at least one potential DDI. The mean number of concomitant medications was 4.8 (0 –19). The mean...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Conviction in the face of affliction: a case series of Jehovah ’s Witnesses with myeloid malignancies
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia
AbstractHeparin-induced thrombocytopenia (HIT) is a serious complication of the administration of heparin and its derivatives. Non-heparin anticoagulants such as argatroban and fondaparinux are widely used in the management of HIT to compare the effectiveness of argatroban and fondaparinux in the resolution of thrombocytopenia and to compare clinical outcomes in patients with isolated HIT. A retrospective cohort analysis was performed at King Abdulaziz Medical City (KAMC) on patients diagnosed with isolated HIT between 31 Jan, 2014 and 30 June, 2017. Demographics data, non-heparin anticoagulants, related laboratory results...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus
In this study, we analyzed the efficacy and side effect of sirolimus on refractory/relapsed aPRCA and investigated the possible mechanism of sirolimus on immune regulation. Twenty-one patients with refractory/relapsed aPRCA were enrolled in this study and were administered with sirolimus. Totally, 76.2% of patients responded to the sirolimus with 42.9% complete response during the experimental period. The median time for reaction was 4  months. Side effects were tolerable including infections; mild oral mucositis; sinus tachycardia, the increase of creatinine, transaminase, triglyceride, or cholesterol; and thrombocyt...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database
In conclusion, incidence of IHD requires closer monitoring in nilotinib-treated patients. More detailed investigations for determining the most useful tool to predict VAE incidence and long-term analysis of therapy-related VAE cases are needed for improving safety during TKI therapy. (Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Localized pain-causing JAK2 -V617F-positive myeloproliferation with normal peripheral blood values
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Hypertransaminasemia revealing a clinically silent muscular dystrophy in a child with sickle cell disease
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation
AbstractProgrammed death 1 (PD-1) activation triggers an immune checkpoint resulting in inhibition of T cells that leads to peripheral tolerance. SomePD-1 polymorphisms have been described and associated with the development of autoimmune diseases or cancer predisposition, but there are few data concerning the relevance of such polymorphisms on the clinical outcome after allogeneic hematopoietic stem cell transplant (alloHSCT). We analyzed the distribution of the SNPs PD-1.1G/A (rs36084323) and PD-1.3G/A (rs11568821) genotypes of the donor in a cohort of 1485 alloHSCT from HLA-identical sibling donors. We found an increase...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Severe anemia after trans-catheter arterial chemoembolization —an unusual presentation of hemoglobin Zurich
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment
In this study, we investigated the effect of CD49d and CXCR4 expressions on survival of CLL cells. Primary CLL cells were cultured with CD49d ligand, VCAM-1, or bone marrow stromal cells (BMSCs); then, apoptosis and immunophenotype analyses were performed. VCAM-1 treatment could not induce direct apoptosis protection or immunophenotype change on the CD49d-expressing CLL cells, but resulted in actin reorganization. The BMSC-induced apoptosis protection was independent from the presence of CD49d expression of CLL cells, but showed an inverse correlation with their CXCR4 expression level. We suppose that CD49d contributes to ...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis
AbstractBone marrow fibrosis (MF) in myelodysplastic syndromes (MDS) is associated with an adverse prognosis. It is likely that molecular changes similar to those in primary myelofibrosis (PMF) lead to MDS-MF, but gene expression profiling has not yet been carried out. We analysed bone marrow biopsy samples by PCR, qPCR (45 transcripts per sample), and immunohistochemistry from MDS patients with fibrosis (n = 70/119; including 19/70 MF0 >  MF follow-up cases), MDS without fibrosis (n = 49/119), and 33 controls. SRSF2 and JAK2 mutations were detectable in up to 13% including 3/19...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Routine surveillance imaging in follicular lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Would you think of histiocytic sarcoma in this fine-needle aspiration?
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Drug-induced liver failure due to rivaroxaban
(Source: Annals of Hematology)
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis
AbstractAlthough the survival rate of diffuse large B cell lymphoma (DLBCL) has increased with years, there are still patients who do not achieve complete remission or who relapse, especially patients with activated B cell-like (ABC) DLBCL. Bortezomib, a proteasome inhibitor, has shown activity in diffuse large B cell lymphoma, especially in the subtype of ABC DLBCL. We conducted a meta-analysis to compare the efficacy and adverse events in bortezomib-containing regimens with standard R-CHOP regimen in treating DLBCL. Our results show that comparing to standard R-CHOP regimen, bortezomib-containing regimen could not prolon...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study
AbstractIn a prospective randomized study, treatment for aplastic anemia (AA) with rabbit antithymocyte globulin (r-ATG) and cyclosporine showed inferior hematological response and survival in comparison to horse antithymocyte globulin (h-ATG) and cyclosporine. However, h-ATG was discontinued in most Asian, South American, and European countries, where r-ATG became the only ATG formulation available. We retrospectively evaluated consecutive patients with acquired AA who received either rabbit (n = 170) or horse (n = 85) ATG and cyclosporine for first-line treatment from 1992 to 2014 in seven ref...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Fatigue at baseline is associated with geriatric impairments and represents an adverse prognostic factor in older patients with a hematological malignancy
AbstractProspective data on fatigue in elderly persons with a hematological malignancy are rare. We aimed to determine the prevalence of fatigue and its association with clinical outcome and geriatric impairments in older individuals newly diagnosed with blood cancer. The EORTC QLQ-C30 and a multidimensional geriatric assessment (MGA) were performed in parallel in 149 consecutive patients aged>  67 years (median 77.8 years) at Innsbruck Medical University between January 2009 and April 2016. Fatigue as defined by EORTC QLQ-C30 was the most prevalent symptom (84%) and was significantly associated with se...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
This study aimed to answer whether the omission of vincristine due to neurotoxicity affects patient outcome. A Swedish cohort of patients primarily treated with curative intent for DLBCL or high-grade malignant B cell lymphoma was retrospectively analyzed. In total, 541 patients treated between 2000 and 2013 were included. Omission of VCR was decided in 95 (17.6%) patients and was more often decided during the last three cycles (n = 86, 90.5%). The omission of VCR did not affect disease-free or overall survival neither in the whole cohort nor in elderly patients. On the contrary, the relative dose intensity o...
Source: Annals of Hematology - October 5, 2018 Category: Hematology Source Type: research

Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma
AbstractAutologous stem cell transplant (ASCT) is standard consolidation therapy in management of multiple myeloma (MM) patients. We reviewed records of all consecutive MM patients who underwent ASCT with high-dose melphalan at our center from year 2002 to 2016. A total of 141 ASCT were conducted (90 males and 51 females) with median age of 55  years (23–68 years). Median time from diagnosis to transplant was 7 months (3–79), with majority of patients underwent transplant in first remission, while 17 (12%) patients received transplant beyond first remission. Eighty-three percent patients obtained...
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine
(Source: Annals of Hematology)
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma
AbstractThe standard treatment in elderly patients with diffuse large B cell lymphoma (DLBCL) has not yet been finely established. We investigated the efficacy and safety of rituximab with a reduced-dose of EPOCH chemotherapy in elderly patients who had advanced DLBCL with high IPI scores. The dose of 70% EPOCH was given to patients aged 75 to 79  years, and dose of 50% to patients aged over 80 years. Thirty-one patients with a median age of 79 years (range 75–86 years) were enrolled. Patients received a median of 6 cycle’s chemotherapy. The complete response rate was 71.0%. The 3-year ...
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events
AbstractWe investigated the median estimated glomerular filtration rate (eGFR) changes in chronic myeloid leukemia (CML) patients treated front line with tyrosine kinase inhibitors (TKIs). A large cohort of 397 patients —320 treated front line with imatinib, 25 with dasatinib, and 53 with nilotinib—was retrospectively analyzed at a single institution. The eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation for all patients at baseline and then at 6 and 12 months, and at the last follow-up. Taking into account eGFR changes during the first year of treatment and ex...
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis
(Source: Annals of Hematology)
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment
(Source: Annals of Hematology)
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy
We report here on 22 APL patients treated with prolonged ATRA-ATO therapy at the time of disease relapse. Twenty patients obtained molecular complete remission (CRm) after 2 cycles (90%). Of these, two patients underwent hematopoietic stem cell transplant (HSCT) while the remaining proceeded to receive additional cycles (up to a total of 5) of ATRA-ATO. With a median follow-up of 58  months from the time of relapse (range: 21–128 months), the 4-year OS probability was 0.85 (95% CI 0.61–0.94), DFS was 0.74 (95% CI 0.49–0.88), and EFS 0.68 (95% CI 0.45–0.83). Two patients were resistant to A...
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study
AbstractVenous thromboembolism (VTE) is a well-recognized complication in pediatric oncology patients. Studies in adult oncology patients have suggested a potential negative association between VTE and survival, but this association has not been examined in pediatric patients yet. The aim of this study was to assess the association of VTE with survival in pediatric oncology patients. Data from all pediatric oncology patients treated at the two tertiary care centers in Atlantic Canada were pooled to create a population-based cohort. The association between VTE and survival was analyzed using a Cox proportional hazards model...
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS
In this study, we set out to assess whether proteasome concentration and chymotrypsin-like (ChT-L) activity could serve as potential biomarkers defining the likelihood of response to treatment with bortezomib, in order to identify patients who are more likely to respond to treatment with PI. We analysed proteasome concentration and ChT-L activity in the plasma of 78 patients with newly diagnosed MM during treatment with or without proteasome inhibitors. Values of all the studied parameters in the group of responders decreased sharply from the initial levels already after the third cycle of chemotherapy and remained signifi...
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research

Monotypic and IgH -rearranged lymphoplasmacytic cells restricted to the light zone of germinal centers: an early (in situ?) marginal zone lymphoma?
(Source: Annals of Hematology)
Source: Annals of Hematology - August 13, 2018 Category: Hematology Source Type: research